Common use of Confidentiality and Intellectual Property Clause in Contracts

Confidentiality and Intellectual Property. The Parties undertake to abide by all applicable laws associated with personal data protection and use and with data privacy while performing hereunder. The rules of processing personal data, in particular personal data of the Participants, are set out in Appendix No. 2 hereto. During the term of this Agreement and for the period of ten (10) years from the end of the Clinical Trial, the Principal Investigator and the Site shall keep confidential any information received from the Sponsor or generated as part of the Clinical Trial (“Confidential Information”). The above restriction shall not apply to Confidential Information which: has been made public without the involvement of the Principal Investigator or the Site; has already been in the possession of the Principal Investigator or the Site; is required to be disclosed by law; has been provided to the Principal Investigator or the Site in accordance with the law; has been disclosed in accordance with this Agreement. The results and data of the Clinical Trial conducted hereunder shall be the sole property of the Sponsor. The Principal Investigator agrees to provide to the Sponsor any Trial results and data in the form agreed with the Sponsor. The Sponsor will publish information about the Clinical Trial, consisting only of the data that may be made available to the public, at the following website: xxx.xxxxxxxxxxxxxx.xxx. The published information will be publicly available on the said website before the first Participant is enrolled into the Clinical Trial. The Sponsor shall ensure that the published data about the Clinical Trial are up to date in order to provide complete and valid information. The Site may publish basic information about the Clinical Trial on its website, to the extent equivalent to the clinical trial information published at xxx.xxxxxxxxxxxxxx.xxx. Any publication or public presentation of the Trial results by the Principal Investigator requires prior consent from the Sponsor. or The Principal Investigator undertakes to publish or present the results of the Clinical Trial to the public on the terms set out in this Agreement. The Principal Investigator undertakes to provide the Sponsor, forty-five (45) days in advance, with written notice before submitting any materials for publication or presentation, in order to enable the Sponsor to review draft abstracts and manuscripts for publication (which includes, in particular, slides and texts of oral or other public presentations), hereinafter referred to as the "Presentation", reporting any results of the Clinical Trial. The Sponsor has the right to review and provide comments to any Presentation. The Principal Investigator agrees to include the Sponsor's comments in the Presentation only if it is necessary for the protection of Confidential Information, personal data or intellectual property, provided that such changes must not be against the reliability of the data, the law, as well as the safety and welfare of the Participants. The Sponsor acknowledges that it has no right to request the deletion or correction of the information contained in the Presentation, except where such deletion or correction is necessary for reasons related to data confidentiality, data protection, or intellectual property protection. The Parties agree to cooperate in good faith in order to discuss and resolve any contentious issues. At the Sponsor's request, the Sponsor will be named as the sponsor of the Clinical Trial. If the Sponsor reports that the Presentation submitted for review contains content suitable for patent protection, the Sponsor shall immediately indicate such content to the Principal Investigator, and then the Principal Investigator shall refrain from publishing the Presentation for further ninety (90) days. If requested by the Sponsor and at its expense, the Principal Investigator shall use its best efforts to assist the Sponsor in filing a patent application with respect to such content with the relevant patent office prior to any publication. To the extent that the participation of the Principal Investigator in the Clinical Trial is part of a multicentre trial, the Principal Investigator agrees that the initial Presentation of the results will take place only simultaneously with other centres, unless prior written consent is obtained from the Sponsor for the Presentation of separate results. The Sponsor will inform the Principal Investigator as to the suggested dates of any Presentation in the event that clinical trials are still ongoing in trial centres other than the Site. The Principal Investigator may publish the results of the Clinical Trial in accordance with this Agreement if the joint publication is not completed within twelve (12) months after the conclusion of the Clinical Trial in all centres conducting thereof and the closure of the database.

Confidentiality and Intellectual Property. The Parties undertake to abide by all applicable laws associated with personal data protection and use and with data privacy while performing hereunder. The rules of processing personal data, in particular personal data of the Participants, are set out in Appendix No. 2 hereto. During the term of this Agreement and for the period of ten (10) years from the end of the Clinical Trial, the Principal Investigator Investigator, the Institution, and the Site shall keep confidential any information received from the Sponsor or generated as part of the Clinical Trial (“Confidential Information”). The above restriction shall not apply to Confidential Information which: has been made public without the involvement of the Principal Investigator Investigator, the Institution, or the Site; has already been in the possession of the Principal Investigator Investigator, the Institution, or the Site; is required to be disclosed by law; has been provided to the Principal Investigator Investigator, the Institution, or the Site in accordance with the law; has been disclosed in accordance with this Agreement. The results and data of the Clinical Trial conducted hereunder shall be the sole property of the Sponsor. The Principal Investigator agrees to provide to the Sponsor any Trial results and data in the form agreed with the Sponsor. The Sponsor will publish information about the Clinical Trial, consisting only of the data that may be made available to the public, at the following website: xxx.xxxxxxxxxxxxxx.xxx. The published information will be publicly available on the said website before the first Participant is enrolled into the Clinical Trial. The Sponsor shall ensure that the published data about the Clinical Trial are up to date in order to provide complete and valid information. The Site and the Institution may publish basic information about the Clinical Trial on its websitetheir websites, to the extent equivalent to the clinical trial information published at xxx.xxxxxxxxxxxxxx.xxx. Any publication or public presentation of the Trial results by the Principal Investigator requires prior consent from the Sponsor. or The Principal Investigator undertakes to publish or present the results of the Clinical Trial to the public on the terms set out in this Agreement. The Principal Investigator undertakes to provide the Sponsor, forty-five (45) days in advance, with written notice before submitting any materials for publication or presentation, in order to enable the Sponsor to review draft abstracts and manuscripts for publication (which includes, in particular, slides and texts of oral or other public presentations), hereinafter referred to as the "Presentation", reporting any results of the Clinical Trial. The Sponsor has the right to review and provide comments to any Presentation. The Principal Investigator agrees to include the Sponsor's comments in the Presentation only if it is necessary for the protection of Confidential Information, personal data or intellectual property, provided that such changes must not be against the reliability of the data, the law, as well as the safety and welfare of the Participants. The Sponsor acknowledges that it has no right to request the deletion or correction of the information contained in the Presentation, except where such deletion or correction is necessary for reasons related to data confidentiality, data protection, or intellectual property protection. The Parties agree to cooperate in good faith in order to discuss and resolve any contentious issues. At the Sponsor's request, the Sponsor will be named as the sponsor of the Clinical Trial. If the Sponsor reports that the Presentation submitted for review contains content suitable for patent protection, the Sponsor shall immediately indicate such content to the Principal Investigator, and then the Principal Investigator shall refrain from publishing the Presentation for further ninety (90) days. If requested by the Sponsor and at its expense, the Principal Investigator shall use its best efforts to assist the Sponsor in filing a patent application with respect to such content with the relevant patent office prior to any publication. To the extent that the participation of the Principal Investigator in the Clinical Trial is part of a multicentre trial, the Principal Investigator agrees that the initial Presentation of the results will take place only simultaneously with other centres, unless prior written consent is obtained from the Sponsor for the Presentation of separate results. The Sponsor will inform the Principal Investigator as to the suggested dates of any Presentation in the event that clinical trials are still ongoing in trial centres other than the Site. The Principal Investigator may publish the results of the Clinical Trial in accordance with this Agreement if the joint publication is not completed within twelve (12) months after the conclusion of the Clinical Trial in all centres conducting thereof and the closure of the database.

Confidentiality and Intellectual Property. The Parties undertake to abide by all applicable laws associated with personal data protection and use and with data privacy while performing hereunder. The rules of processing personal data, in particular personal data of the Participants, are set out in Appendix No. 2 hereto. During the term of this Agreement and for the period of ten (10) years from the end of the Clinical Trial, the Principal Investigator and the Site Institution shall keep confidential any information received from the Sponsor or generated as part of the Clinical Trial (“Confidential Information”). The above restriction shall not apply to Confidential Information which: has been made public without the involvement of the Principal Investigator or the SiteInstitution; has already been in the possession of the Principal Investigator or the SiteInstitution; is required to be disclosed by law; has been provided to the Principal Investigator or the Site Institution in accordance with the law; has been disclosed in accordance with this Agreement. The results and data of the Clinical Trial conducted hereunder shall be the sole property of the Sponsor. The Principal Investigator agrees to provide to the Sponsor any Trial results and data in the form agreed with the Sponsor. The Sponsor will publish information about the Clinical Trial, consisting only of the data that may be made available to the public, at the following website: xxx.xxxxxxxxxxxxxx.xxx. The published information will be publicly available on the said website before the first Participant is enrolled into the Clinical Trial. The Sponsor shall ensure that the published data about the Clinical Trial are up to date in order to provide complete and valid information. The Institution and the Site may publish basic information about the Clinical Trial on its websitetheir websites, to the extent equivalent to the clinical trial information published at xxx.xxxxxxxxxxxxxx.xxx. Any publication or public presentation of the Trial results by the Principal Investigator requires prior consent from the Sponsor. or The Principal Investigator undertakes to publish or present the results of the Clinical Trial to the public on the terms set out in this Agreement. The Principal Investigator undertakes to provide the Sponsor, forty-five (45) days in advance, with written notice before submitting any materials for publication or presentation, in order to enable the Sponsor to review draft abstracts and manuscripts for publication (which includes, in particular, slides and texts of oral or other public presentations), hereinafter referred to as the "Presentation", reporting any results of the Clinical Trial. The Sponsor has the right to review and provide comments to any Presentation. The Principal Investigator agrees to include the Sponsor's comments in the Presentation only if it is necessary for the protection of Confidential Information, personal data or intellectual property, provided that such changes must not be against the reliability of the data, the law, as well as the safety and welfare of the Participants. The Sponsor acknowledges that it has no right to request the deletion or correction of the information contained in the Presentation, except where such deletion or correction is necessary for reasons related to data confidentiality, data protection, or intellectual property protection. The Parties agree to cooperate in good faith in order to discuss and resolve any contentious issues. At the Sponsor's request, the Sponsor will be named as the sponsor of the Clinical Trial. If the Sponsor reports that the Presentation submitted for review contains content suitable for patent protection, the Sponsor shall immediately indicate such content to the Principal Investigator, and then the Principal Investigator shall refrain from publishing the Presentation for further ninety (90) days. If requested by the Sponsor and at its expense, the Principal Investigator shall use its best efforts to assist the Sponsor in filing a patent application with respect to such content with the relevant patent office prior to any publication. To the extent that the participation of the Principal Investigator in the Clinical Trial is part of a multicentre trial, the Principal Investigator agrees that the initial Presentation of the results will take place only simultaneously with other centres, unless prior written consent is obtained from the Sponsor for the Presentation of separate results. The Sponsor will inform the Principal Investigator as to the suggested dates of any Presentation in the event that clinical trials are still ongoing in trial centres other than the Site. The Principal Investigator may publish the results of the Clinical Trial in accordance with this Agreement if the joint publication is not completed within twelve (12) months after the conclusion of the Clinical Trial in all centres conducting thereof and the closure of the database.